Intracervical Vasopressin for Completion of Hysteroscopic Removal of Retained Products of Conception

What this Trial Is About

This research evaluates whether injecting a medicine called vasopressin into the cervix during surgery helps improve the removal of retained products of conception (RPOC). RPOC happens when pregnancy tissue remains in the uterus after miscarriage, abortion, or delivery. The study compares the effect of vasopressin to a placebo during a hysteroscopic procedure, which uses a small camera to look inside the uterus and remove these tissues. Participants will be randomly assigned to receive either an intracervical injection of vasopressin or a saline placebo during their hysteroscopic removal procedure. The vasopressin dose is a 20 mL dilute solution containing 5 units of the drug. The study will measure whether the procedure can be completed hysteroscopically without needing to switch to a suction method due to bleeding or poor visibility. Secondary outcomes include blood loss during the operation, surgery duration, and fluid deficit volume. During the study, researchers will collect information from medical records about the surgical procedure and outcomes. Participants can expect assessments of bleeding, operation time, and fluid usage. The main focus is on whether the hysteroscopic removal completes successfully. The study is scheduled to start in late 2025 and continue through 2026, involving women aged 18 to 51 undergoing surgical treatment for RPOC.

Intracervical Vasopressin